Trials / Completed
CompletedNCT02245529
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
Secotex ®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 982 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving patients treated with Secotex® (Tamsulosin) in "real life" settings. The aim of a PEM is to monitor the safety profile of Secotex® in a cohort of patients with Benign Prostatic Hyperplasia as used in general practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tamsulosin |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2005-09-01
- First posted
- 2014-09-19
- Last updated
- 2014-09-19
Source: ClinicalTrials.gov record NCT02245529. Inclusion in this directory is not an endorsement.